Immunovaccine Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
Immunovaccine’s DepoVax™ platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
'+p(a[c].innerHTML)+"
",y&&(b=J?b+(''+f[c].getAttribute("aria-label")+"
"):b+(''+f[c].getAttribute("aria-label")+"
"))):a[c].innerText?(t&&(b+=''+k[c].innerText+"
"),b+=''+a[c].innerText+"
",y&&(b+=''+f[c].innerText+"
")): (t&&(b+=''+k[c].textContent+"
"),b+=''+a[c].textContent+"
",y&&(b+=''+f[c].textContent+"
"));H&&(b+='':">")+'Reply':">")+'Retweet':">")+"Favorite
");I&&void 0!==h[c]&&(b+='© 2016 All Rights Reserved By Biotech and Money